FRM
BMRN icon

Fox Run Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Fox Run Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-18,361
Closed -$1.01M – 929
2025
Q2 		$1.01M Sell
18,361
-4,748
-21% -$280K 0.17% 186
2025
Q1 		$1.63M Buy
23,109
+14,893
+181% +$1M 0.25% 62
2024
Q4 		$540K Sell
8,216
-6,150
-43% -$412K 0.1% 413
2024
Q3 		$1.01M Buy
14,366
+8,670
+152% +$725K 0.22% 121
2024
Q2 		$469K Sell
5,696
-4,254
-43% -$354K 0.09% 432
2024
Q1 		$869K Sell
9,950
-831
-8% -$74.4K 0.19% 176
2023
Q4 		$1.04M Buy
10,781
+5,780
+116% +$511K 0.27% 76
2023
Q3 		$442K Sell
5,001
-13,401
-73% -$1.19M 0.13% 303
2023
Q2 		$1.6M Buy
+18,402
New +$1.73M 0.45% 11
2022
Q3 		– Sell
-2,741
Closed -$227K – 612
2022
Q2 		$227K Sell
2,741
-8,603
-76% -$685K 0.11% 387
2022
Q1 		$875K Buy
11,344
+3,862
+52% +$323K 0.49% 17
2021
Q4 		$661K Buy
7,482
+4,321
+137% +$357K 0.39% 42
2021
Q3 		$244K Buy
+3,161
New +$249K 0.15% 303
2016
Q3 		– Sell
-10,600
Closed -$825K – 499
2016
Q2 		$825K Buy
10,600
+3,200
+43% +$272K 0.4% 23
2016
Q1 		$610K Buy
+7,400
New +$602K 0.41% 43

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fox Run Management's BMRN Position: Q3 2025 in Review

Fox Run Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 18,361 shares — an estimated $1.01M sold.

Fox Run Management first reported a position in BMRN in Q1 2016 and held it in 15 quarters. The position peaked at $1.63M in Q1 2025. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

  • Fox Run Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Fox Run Management sold 18,361 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $1.01M.
  • Fox Run Management first reported a position in BioMarin Pharmaceuticals in Q1 2016 and held it in 15 quarters.
  • Fox Run Management's BioMarin Pharmaceuticals position peaked at $1.63M in Q1 2025.
  • 576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on Fox Run Management's 13F filing for Q3 2025, filed 12 Nov 2025.